$GSKA potential "ABC" pattern has been located here at a level where two previous support levels were broken. Price is near the 11-2023 support level. Looking for a retracement here to two targets overtime.
Key facts today
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
16.25 MXN
106.55 B MXN
655.75 B MXN
3.73 B
About GSK PLC ORD GBP0.3125
Sector
CEO
Emma N. Walmsley
Headquarters
London
Website
ISIN
GB00BN7SWP63
FIGI
BBG0125C29F4
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GSK 1-2 wk swing IdeaNYSE:GSK has set of a daily trigger with a 5/10 ema crossover after a positive earnings report.
During my planning for this idea, I needed to zoom WAY out to the monthly chart in order to understand these levels a bit more. Screen shot of the monthly below:
It turns out that last week's close
GSKNot a recommendation. Held this for a while with very little movement, now GSK as started going up, div yield is over 3.3%
Long GSK - Euro Drug Hype Cycle approachesPlaying short term trade presuming positive news in a week or two.
Shares would return to the range highs near $37.00
Ex-Dividend Date later this week
GSK (GSK) Outperformed Market ReturnsIn the latest trading session, GSK (GSK) closed at $37.10, marking a +1.23% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.63% for the day. Elsewhere, the Dow gained 0.59%, while the tech-heavy Nasdaq added 0.39%.
Prior to today's trading, shares of the dru
GSK looking bullish! Buy volume at resistance at this point in the falling channel should help propel the price to an initial measured target if $47 which would be thr breakout point of an even bigger bullish macro setup.
GSK with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for GSK after a negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 80%.
Long Glaxo Smith Kline (NAS:GSK) looks very good risk returnUsing longer term Auction Market Theory to construct longer term meaningful #VolumeProfiles can sometimes provide exceptional risk reward setups.
One has just popped up in GSK according to my read anyway.
Now price has returned into the longer term Value Area there's a very good chance price will
$GSK: Weekly trend signalGreat reward to risk in this weekly chart setup in $GSK, worth a shot, you can probably play it with options to not allocate too much capital in this idea and have limited downside risk. An ITM put spread or some kind of Iron Butterfly OTM can both reap the passage of time profiting from Theta drop
$GSK with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $GSK after a Positive over reaction following its earnings release placing the stock in drift B.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
G
17RI
GLAXOSMITHKLINE CAPITAL PLC 4.25% GTD SNR EMTN 18/12/45Yield to maturity
6.06%
Maturity date
Dec 18, 2045
G
GSK3981911
GlaxoSmithKline Capital, Inc. 4.2% 18-MAR-2043Yield to maturity
5.91%
Maturity date
Mar 18, 2043
G
83GI
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 10/04/2042Yield to maturity
5.58%
Maturity date
Apr 10, 2042
G
GSK.GJ
GlaxoSmithKline Capital, Inc. 6.375% 15-MAY-2038Yield to maturity
5.33%
Maturity date
May 15, 2038
G
71ZC
GLAXOSMITHKLINE CAPITAL PLC 6.375% GTD SNR EMTN 09/03/39Yield to maturity
5.20%
Maturity date
Mar 9, 2039
G
GSK4632357
GlaxoSmithKline Capital, Inc. 3.625% 15-MAY-2025Yield to maturity
4.93%
Maturity date
May 15, 2025
G
AG99
GLAXOSMITHKLINE CAPITAL PLC 5.25% GTD SNR EMTN 19/12/2033Yield to maturity
4.71%
Maturity date
Dec 19, 2033
Explore more bonds
Curated watchlists where GSK1/N is featured.
Female-led stocks: Who rules the world?
34 No. of Symbols
UK stocks: Best of British
28 No. of Symbols
See all sparks
Frequently Asked Questions
The current price of GSK1/N is 367.94 MXN — it hasn't changed in the past 24 hours. Watch GSK PLC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange GSK PLC stocks are traded under the ticker GSK1/N.
GSK1/N stock hasn't changed in a week, the last month showed zero change in price, over the last year GSK PLC has showed a 20.62% increase.
We've gathered analysts' opinions on GSK PLC future price: according to them, GSK1/N price has a max estimate of 626.48 MXN and a min estimate of 300.61 MXN. Watch GSK1/N chart and read a more detailed GSK PLC stock forecast: see what analysts think of GSK PLC and suggest that you do with its stocks.
GSK1/N reached its all-time high on Jan 19, 2022 with the price of 590.06 MXN, and its all-time low was 305.05 MXN and was reached on Mar 8, 2023. View more price dynamics on GSK1/N chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GSK1/N stock is 0.00% volatile and has beta coefficient of 0.76. Track GSK PLC stock price on the chart and check out the list of the most volatile stocks — is GSK PLC there?
Today GSK PLC has the market capitalization of 1.38 T, it has increased by 1.18% over the last week.
Yes, you can track GSK PLC financials in yearly and quarterly reports right on TradingView.
GSK PLC is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
GSK1/N earnings for the last quarter are 13.09 MXN per share, whereas the estimation was 11.56 MXN resulting in a 13.29% surprise. The estimated earnings for the next quarter are 4.93 MXN per share. See more details about GSK PLC earnings.
GSK PLC revenue for the last quarter amounts to 211.10 B MXN, despite the estimated figure of 211.18 B MXN. In the next quarter, revenue is expected to reach 194.48 B MXN.
GSK1/N net income for the last quarter is −1.53 B MXN, while the quarter before that showed 27.20 B MXN of net income which accounts for −105.62% change. Track more GSK PLC financial stats to get the full picture.
GSK PLC dividend yield was 4.00% in 2023, and payout ratio reached 47.69%. The year before the numbers were 4.26% and 16.49% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 25, 2024, the company has 70.21 K employees. See our rating of the largest employees — is GSK PLC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GSK PLC EBITDA is 238.76 B MXN, and current EBITDA margin is 30.62%. See more stats in GSK PLC financial statements.
Like other stocks, GSK1/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GSK PLC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GSK PLC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GSK PLC stock shows the neutral signal. See more of GSK PLC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.